Regeneron’s clinical trials are at the core of this mission. Regeneron is grateful to all clinical trial participants — ...

Nipocalimab was granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease based on results from the Phase 2 DAHLIAS study ...

Senators push a bill to increase federal research on menopause, coordinate the federal government’s existing programs ...

Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and <a target=_blank href= ...

A new high-resolution neural recording method developed by Johns Hopkins APL and the School of Medicine detects neural ...

Cytophone clinical prototype The ... an invasive blood sample. Now, a research collaboration from USA and Cameroon has ...

Yamaha Motor Co., Ltd. (Tokyo: 7272) announced today the upcoming release of the new CELL HANDLER(TM) 2, a cell picking and imaging system set to launch in March 2025. This advanced system aims to ...

San Francisco–based Ossium Health has carried out three transplants for cancer patients using stem cells from deceased donors ...

Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...

Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.

Zetomipzomib: Selective Immunoproteasome Inhibitor PORTOLA – Phase 2a clinical trial of zetomipzomib ... to complete the DBTP of the PORTOLA trial without modification. However, the FDA has placed a ...

Q3 2024 Earnings Call Transcript November 7, 2024 Geron Corporation beats earnings expectations. Reported EPS is $-0.04, ...